Monthly Archives: July 2020

Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments

Jia Xie, PhD, a prominent researcher at Scripps Research responsible for inventing a collection of new technologies for antibody drug discovery and cell therapy
Alexey V. Stepanov, PhD, a leading research expert in developing personalized therapeutic tools for lymphoproliferative disease using cell therapy
Appointments bring valuable expertise to Scientific Advisory Board as the Company works to advance development of XCART through preclinical development and potentially into a Phase 1 trial

FRAMINGHAM, MA / ACCESSWIRE / July 30, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the strengthening of its Scientific Advisory Board ("SAB") with the appointment of Jia Xie, PhD and Alexey V. Stepanov, PhD.

"We are pleased to welcome Dr. Xie and Dr. Stepanov to our Scientific Advisory Board. They are both leading experts in their respective fields of research and will provide valuable insight as we work to advance our XCART platform through preclinical development and potentially into a Phase 1 study," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

Dr. Xie has been working at Scripps Research since 2011 and currently serves as a Senior Scientist at the Department of Chemistry. He is specialized in new platform development and therapeutic molecule discovery. In the past, Dr. Xie and his team have invented a collection of new technologies for antibody drug discovery and cell therapy, which were licensed by biotech companies and led to joint collaboration efforts with large pharmaceutical companies.

"There is no doubt that CAR T cell therapies have revolutionized the treatment of cancer. However, there are shortcomings with current therapies, and I believe there is significant room for improvement. The ability to target unique B-cell receptors, like the XCART technology is designed to do, has significant clinical potential and may lead to therapies with more desirable safety profiles," commented Dr. Xie, Senior Staff Scientist, Chemistry, Scripps Research.

Dr. Stepanov is a leading research expert in developing personalized therapeutic tools for lymphoproliferative diseases using immunotoxins or adoptive cell therapy. He currently serves as a Senior Staff Scientist in the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. At the same time, Dr. Stepanov maintains a Senior Staff Scientist position in the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology in Russia. Dr. Stepanov directs a group in the laboratory of biocatalysis at the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry that focuses on developing novel approaches for safe and controlled adoptive immunotherapy by CAR T cells. Dr. Stepanov is a professional scientific collaborator of Dr. Richard Lerner's laboratory in Scripps Research.

Dr. Stepanov stated, "I am encouraged by the preclinical data generated to date by the XCART platform and believe it provides a differentiated and potentially beneficial approach to the treatment of B-cell lymphomas. I look forward to working closely with the Xenetic team to advance this program through preclinical development and into the clinic."

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding: the Company belief that it is strategically well-positioned to execute on pathway to advance the XCART platform technology through preclinical development and potentially into a Phase 1 trial; the Company's collaborations with Scripps Research and Pharmsynthez and the multiple academic institutions in Russia and Belarus, including the Company's belief that such collaborations are critical components of the Company's overall development plan for XCART, the Company's expectations that such collaborations provide the Company access to partners that have the capability and capacity to expeditiously and cost-effectively advance XCART through preclinical development, and the Company's expectations that such collaborations will provide access to patients and CART T clinical manufacturing suites which will potentially allow the Company to enter into a Phase 1 dosing study; the Company's belief that the agreement with Scripps Research will provide access to a team with extensive expertise in the CAR T space who will assist in the design and implementation of the pre-clinical development program for XCART; the Company's plans to work with personnel in Dr. Richard Lerner's lab; expectations that the agreement with Pharmsynthez will involve institutions with extensive expertise in anti-idiotype approaches to lymphoma as well as CAR T development and manufacturing; the Company's plans to, in collaboration with Pharmsynthez and the Belarus Institutions, conduct an exploratory trial to define and evaluate the XCART front-end process of target identification, screening and lead characterization, in a real-world clinical setting; expectations that the collaborations may be expanded to include development and qualification of manufacturing processes for producing autologous XCART T-cells; statements that if successful, the Company has the potential to expand the clinical study component to dose a number of NHL patients in a Phase 1 dosing study; expectations that the data generated under the Belarus collaboration may support an IND filing in the United States; statements that the Company is focused on process development for autologous T cell manufacturing and generation of preclinical data covering the overall XCART workflow; the Company's belief that by augmenting preclinical data with insights gained from conduct of the XCART workflow in a human exploratory setting, the Company can strengthen the data sets with which it approaches discussions with the FDA and support its IND filing to advance its U.S. development strategy for XCART; the Company's plans to initially apply the XCART technology to advance cell-based therapeutics by targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas, the Company's expectations that XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications, the Company's plans to leverage PolyXen® by partnering with biotechnology and pharmaceutical companies, and the Company's expectation regarding receipt of royalty payments under the exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the acquisition of XCART; (2) uncertainty of the expected financial performance of the Company following completion of the acquisition of XCART; (3) failure to realize the anticipated potential of the XCART technology; (4) the ability of the Company to implement its business strategy; (5) failure of Scripps Research and/or Pharmsynthez or the other academic institutions in Belarus and Russia (as applicable) to perform their obligations under the respective agreements; (6) failure of the Company and Pharmsynthez to reach agreements with the contract sites on terms favorable to the Company, or at all, and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

ReleaseID: 599431

Gatling to Commence AI Target Generation at Larder Gold Project, Ontario

VANCOUVER, BC / ACCESSWIRE / July 30, 2020 / GATLING EXPLORATION INC. (TSXV:GTR)(OTCQX:GATGF) (the "Company" or "Gatling) is pleased to announce it has engaged artificial intelligence (AI) experts, Windfall Geotek, to use its advanced Computer Aided Resource Detection System (CARDS) to identify probable gold targets at the Larder Gold project. The AI targets will be evaluated and explored using traditional exploration techniques in upcoming programs.

Highlights of CARDS Analysis on Larder Gold Project

Large, Prospective Project Area. Gatling's Larder Gold project occupies 3,370 hectares along the Cadillac Larder Lake Break, a prolific structural gold trend. The property hosts three high-grade deposits along the main break, as well as two additional, underexplored gold trends, recently discovered 6 km north.

Robust Database for AI Analysis. AI uses pattern recognition and machine learning to make predictions based off compiled datasets. The Larder project benefits from a vast database of recent and historical data, including: >2,000 drill holes, >90,000 assays, >1,000 surface rock samples, >500 soil samples, as well as geophysics, Lidar and bedrock geology.

Multiple Localized Deposits Provide Important Guidance for AI. The area to be analyzed has numerous deposits including, but not limited to, Agnico Eagle's Upper Beaver, Kerr Addison, Mistango River Resources' Omega Mine and Gatling's 3 high-grade gold deposits: Fernland, Cheminis and Bear. These known gold deposits will be instrumental in guiding the AI, with the goal of highlighting areas on Larder that may be geologically similar to other deposits in the district.

Figure 1. Larder Gold project area with bedrock geology, structures and training points to be included in the CARDS analysis.

About Gatling Exploration

Gatling Exploration is a Canadian gold exploration company focused on advancing the Larder Gold Project, located in the prolific Abitibi greenstone belt in Northern Ontario. The Larder property hosts three high-grade gold deposits along the Cadillac-Larder Lake Break, 35 kilometers east of Kirkland Lake. The project is 100% controlled by Gatling and is comprised of patented and unpatented claims, leases and mining licenses of occupation within the McVittie and McGarry Townships. The 3,370 hectare project area is positioned 7 kilometers west of the Kerr Addison Mine, which produced 11 million ounces of gold. All parts of the Larder property are accessible by truck or all-terrain vehicles on non-serviced roads and trails.

Qualified Person

The technical content of this news release has been reviewed and approved by Nathan Tribble, P. Geo., VP Exploration of Gatling Exploration, and a Qualified Person pursuant to National Instrument 43-101.

ON BEHALF OF THE BOARD OF DIRECTORS,

Nav Dhaliwal, President and CEO

Gatling Exploration Inc.

For further information on Gatling, contact Investor Relations
Telephone: 1-888-316-1050
Email: ir@gatlingexploration.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements: Statements contained in this news release that are not historical facts are forward-looking statements, which are subject to a number of known and unknown risks, uncertainness and other factors that may cause the actual results to differ materially from those anticipated in our forward-looking statements. Although we believe that the expectations in our forward-looking statements are reasonable, actual results may vary, and we cannot guarantee future results, levels of activity, performance or achievements.

SOURCE: Gatling Exploration Inc.

ReleaseID: 599569

The Freedom Bank of Virginia Announces Earnings for the Second Quarter of 2020

FAIRFAX, VA / ACCESSWIRE / July 30, 2020 / The Freedom Bank of Virginia (OTCQX:FDVA), (the "Bank" or "Freedom") today announced net income of $1,525,525, or $0.21 per diluted share, for the three months ended June 30, 2020. This compares to net income of $849,806 or $0.11 per diluted share, for the prior quarter and net income of $509,075 or $0.07 per diluted share for the three months ending June 30, 2019. The Bank reported net income of $2,375,331 or $0.33 per diluted share for the six months ended June 30, 2020 compared to net income of $1,025,062 or $0.14 per diluted share for the six months ended June 30, 2019.

Joseph J. Thomas, President and CEO, commented "The talents of our team at Freedom Bank were in full display in the first half of 2020 as we transitioned to a remote work environment due to COVID-19, yet achieved record loan volume with 510 loans funded through the Small Business Administration's Paycheck Protection Program (PPP loans) totaling $106.37 million and 478 residential mortgage loans funded totaling $173.07 million. Despite the very challenging economic environment, this activity enabled the Bank to grow total loans to $545.72 million, a 35.4% increase, and non-interest income to $5.64 million, a 141.8% increase in the first half of 2020 compared to the same period in 2019. As a result, we reported record earnings of $1.53 million or $0.21 per diluted share in the second quarter of 2020, which translates into a Return on Average Assets of 0.92% and a Return on Average Equity of 9.24%. Freedom also continues to demonstrate exceptional resiliency with strong earnings, additional contributions to our high level of allowance for loan losses at 1.02% of loans held-for-investment (or 1.28% of loans held-for-investment when excluding PPP loans) and a fortress balance sheet with strong capital represented by a Tier 1 Risk Based Capital ratio of 13.90% at the end of the second quarter."

Second Quarter Highlights include:

Net income increased by 79.51% compared to the prior quarter and by 199.67% compared to the same period in 2019. Net income for the second quarter was $1,525,525 or $0.21 per diluted share compared to net income of $849,806 or $0.11 per diluted share in the prior quarter and net income of $509,075 or $0.07 per diluted share for the three months ended June 30, 2019;
Net income for the first six months of 2020 increased by 131.73% compared to the same period in 2019. Net income was $2,375,331 or $0.33 per diluted shares, compared to net income of $1,025,062 or $0.14 per diluted share for the same period in 2019;
Return on Average Assets ("ROAA") was 0.92% for the quarter ended June 30, 2020 compared to 0.68% for the prior quarter and 0.42% for the three months ended June 30, 2019;
Return on Average Equity ("ROAE") was 9.24% for the three months ended June 30, 2020 compared to 5.27% for the prior quarter and 3.36% for the three months ended June 30, 2019;
Total assets were $697.75 million on June 30, 2020, an increase of $197.32 million from December 31, 2019;
Total loans increased by $113.74 million or by 26.33% during the quarter, including $104.59 million of PPP loans. Other loans held-for-investment increased by $6.80 million or by 1.69%, while loans held-for-sale increased by $2.35 million or by 7.96% in the second quarter;
On-balance sheet liquidity, comprising cash and deposits at other banks and available-for sale securities, increased by $48.09 million or 61.03% in the second quarter;
Total deposits increased by $75.22 million or by 18.23% in the second quarter. Non-interest bearing demand deposits increased to $153.84 million and represented 31.53% of total deposits at the end of the quarter;
The net interest margin was 2.93% in the second quarter, lower by 33 basis points compared to the previous quarter and lower by 34 basis points compared to the same period in 2019. The net interest margin was pressured by lower earning asset yields, largely driven by an abundance of liquidity and low yielding PPP loans, partially offset by a reduction in the cost of funds;
The cost of funds was 0.88% for the second quarter, lower by 56 basis points compared to the previous quarter and lower by 78 basis points compared to the same period in 2019, as deposit rates were reduced across the board, the PPP loans generated an influx of non-interest bearing deposits, and the cost of borrowings was reduced by low cost PPP Liquidity Facility Advances;
Non-interest income increased by 37.72% compared to the previous quarter and increased by 133.33% compared to the same period in 2019, primarily due to higher revenue from the sale of mortgage loans,

Swap fee income and higher income from Bank Owned Life Insurance;

Non-interest expenses increased by 13.30% compared to the previous quarter and increased by 23.51% compared to the same period in 2019, primarily due to higher compensation costs related to commissions paid to mortgage loan officers and an increase in mortgage settlement costs. Excluding mortgage costs, non-interest expenses decreased by 3.33% compared to the previous quarter and decreased by 9.18% compared to the same period in 2019;
The Efficiency Ratio was 67.97% for the quarter ended June 30, 2020, compared to 76.15% for the prior quarter and 84.97% for the same period in 2019. Excluding mortgage revenues and mortgage costs, the efficiency ratio was 66.64% for the quarter compared to 83.92% for the prior quarter and 89.42% for the same period in 2019;
The Bank recognized a $705,000 provision for loan losses during the second quarter and the ratio of the allowance for loan and lease losses to loans held-for-investment was 1.02% (or 1.28% excluding PPP loans, which carry a full faith and guarantee by the US Government) compared to 1.16% in the previous quarter. The increase in reserves related to the provision for loan losses was net of loan charge offs of $150,000, and was due to loan growth during the second quarter as well as a deterioration in the economy stemming from COVID-19;
The Bank is well capitalized and capital ratios continue to be strong with a Leverage ratio of 11.23%, Common Equity Tier 1 ratio of 13.90%, Tier 1 Risk Based Capital ratio of 13.90% and a Total Capital ratio of 14.99%.

Net Interest Income

The Bank recorded net interest income of $4.72 million for the second quarter of 2020, an increase of 20.40% compared to the previous quarter, and 25.11% higher than the same period in 2019. The net interest margin in the second quarter of 2020 was 2.93%, lower by 33 basis points compared to the previous quarter and lower by 34 basis points compared to the same period in 2019.

The following factors contributed to the changes in net interest margin during the second quarter of 2020 compared to the previous quarter:

Yields on average earning assets decreased by 80 basis points to 3.75% compared to 4.55% in the previous quarter, primarily due to an abundance of liquidity and a decrease in loan yields during the second quarter, largely due to lower yields on PPP loans. Yields on investment securities and cash declined sharply as well, primarily due to growth in liquid assets, combined with reductions in bond yields and interest paid on cash balances.
Loan yields decreased by 67 basis points to 4.35% from 5.02% in the previous quarter, while yields on investment securities decreased by 11 basis point to 2.51%, from 2.62% in the previous quarter.
Cost of funds decreased by 56 basis points to 0.88%, from 1.44% in the previous quarter, primarily due to an influx of non-interest bearing deposits from PPP loans that were funded in the second quarter, lower costs related to borrowings and interest bearing deposits. Borrowings included term advances from the PPP Liquidity Facility at a fixed rate of 0.35% to fund the PPP loans.

The following factors contributed to the changes in net interest margin during the second quarter compared to the same period in 2019:

Loan yields decreased by 82 basis points to 4.35% from 5.17% in the second quarter of 2019, while yields on investment securities decreased by 29 basis points to 2.51%, from 2.80% in the same period in 2019.
Cost of funds decreased by 78 basis points to 0.88%, from 1.66% in the second quarter of 2019, primarily due to an influx in non-interest bearing deposits from PPP loans funded in the second quarter, lower costs related to borrowings and interest bearing deposits. Borrowings included term advances from the PPP Liquidity Facility at a fixed rate of 0.35% to fund the PPP loans.

As the COVID-19 outbreak spread across the country and the macroeconomic outlook deteriorated, interest rates declined and the Federal Reserve implemented a series of actions in March to stabilize markets. These actions included a reduction in the Federal Funds target by 150 basis points, increased purchases of mortgage backed securities and Treasuries and the announcement of a number of new lending programs. The decline in interest rates has put pressure on yields for all earning assets and while we have reduced deposit and borrowing costs and expect our cost-of-funds to decline, net interest margin will continue to be under pressure.

On March 27, 2020, the President signed H.R. 748, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") into law. Among other provisions, the CARES Act authorized the Payment Protection Program ("PPP"). The PPP provides small businesses with 500 or fewer employees with funds to pay up to eight weeks of payroll costs including benefits, interest on mortgages, rent and utilities. Funds were made available in the form of fully guaranteed 7(a) loans administered by the Small Business Administration ("SBA"), and made by approved SBA lenders. The loan amounts disbursed may be forgiven in whole or in part by the SBA. The interest rate on the PPP loans is 1% and the term varies from two to five years (loan term of five years for PPP loans originated pursuant to the Paycheck Protection Program Flexibility Act, signed into law on June 5, 2020). Additionally, the SBA pays processing fees to the lenders, which vary depending upon the loan amount.

As an approved SBA lender, the Bank participated in the PPP loan program, processed and funded 510 loans with outstanding balances of $106.37 million in the second quarter. The Bank expects to receive total processing fees of approximately $3.23 million from the SBA on the PPP loans. The fees represent approximately 3.09% of PPP loan balances, and will be deferred through the term of the loans. The large volume of PPP loans processed by the Bank lowered our loan yields in the second quarter and will do as long as the loans are on the Bank's balance sheet. The Bank funded the PPP loans with term advances from the PPP Liquidity Facility at a fixed rate of 0.35%.

Non-interest Income

Non-interest income was $3.27 million for the second quarter, higher by 37.72% compared to the previous quarter and higher by 133.33% compared to the same period in 2019. The principal contributor to the increase in non-interest income in the second quarter of 2020 compared to the previous quarter was higher gain-on-sale revenue from mortgage loans, stemming from an increase in mortgage refinancing activity. Other factors that contributed to the increase in non-interest income were swap fees and higher income from Bank Owned Life Insurance.

Non-interest Expenses

Non-interest expenses in the second quarter of 2020 increased by 13.30% compared to the previous quarter and increased by 23.51% compared to the same period in 2019. The increase was largely driven by higher commissions paid to mortgage loan officers and an increase in mortgage settlement costs on higher closed loan volume during the quarter. Excluding mortgage related costs, non-interest expenses decreased by 3.33% compared to the prior quarter and by 8.03% compared to the same period in 2019. Excluding mortgage related costs, non-interest expenses incurred in the first six months of 2020 declined by 9.18% compared to the same period in 2019.

Additional categories of non-interest expenses that changed in the second quarter of 2020 were the following:

Professional fees were higher by 15.69% in the second quarter of 2020 compared to the previous quarter, primarily related to costs incurred in processing PPP loans.
Data processing expenses in the second quarter were higher by 64.21% compared to the previous quarter, primarily due to the increase in loan and deposit activity and asset growth during the quarter.
Advertising expenses in the second quarter of 2020 declined relative to the previous quarter on curtailed media advertising.

The Efficiency Ratio was 67.97% for the quarter ended June 30, 2020, compared to 76.15% for the prior quarter and 84.97% for the same period in 2019. Excluding mortgage revenues and mortgage costs, the efficiency ratio was 66.64% for the quarter compared to 83.92% for the prior quarter and 89.42% for the same period in 2019.

The Efficiency ratio for the first six months of 2020 was 71.97% compared to 87.25% for the same period in 2019. Excluding mortgage related costs and revenues, the efficiency ratio for the first six months of 2020 was 74.43% compared to 89.47% for the same period in 2019.

Asset Quality

Non-accrual loans were $3.89 million or 0.71% of total loans at the end of the second quarter of 2020, compared to $2.16 million or 0.50% of total loans at the end of the prior quarter. There were no troubled debt restructurings ("TDRs") as of June 30, 2020. On June 30, 2020, there was one loan with a book balance of $80,000 that was 90 days or more past due and accruing, equivalent to 0.01% of total loans, compared to $150,000 of loans that were 90 days or more past due and accruing, equivalent to 0.03% of total loans on March 31, 2020. There was no Other Real Estate Owned ("OREO") on the balance sheet as of June 30, 2020. Total non-performing assets (defined as the sum of loans on non-accrual, loans greater than 90 days past due and accruing, loans that are TDRs but not on non-accrual, and OREO assets) were $3.97 million or 0.57% of total assets at June 30, 2020 compared to $2.31 million or 0.43% of total assets, at the end of the previous quarter.

As of June 30, 2020, pursuant to the CARES Act and interagency guidance on loan modifications related to COVID-19, the Bank had granted loan payment deferrals of up to six months to 96 borrowers representing $89.35 million of outstanding loan balances or 17.39% of loans held-for-investment (or 21.84% of loans held-for-investment excluding PPP loans).

Limited COVID-19 At-Risk Industry Exposure
 

Industry

 
Total Outstanding
 
 
% of Total Loans
 
 
Total Deferred Principal Balance
 
 
Deferred Principal Balance as of % of Total Industry
 

 

 
 
 
 
 
 
 
 
 
 
 
 

Retail

 
$
5,341,149
 
 
 
1.04
%
 
$
1,516,941
 
 
 
28.40
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Restaurants

 
$
4,459,916
 
 
 
0.87
%
 
$
886,876
 
 
 
19.89
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Fitness Centers

 
$
6,278,303
 
 
 
1.23
%
 
$
5,768,186
 
 
 
91.87
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Hotels

 
$
5,138,705
 
 
 
1.00
%
 
$
4,738,705
 
 
 
92.22
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Churches

 
$
18,399,927
 
 
 
3.59
%
 
$
8,445,323
 
 
 
45.90
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Subtotal – June 30, 2020

 
$
39,617,999
 
 
 
7.73
%
 
$
21,356,030
 
 
 
53.90
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

The table above shows the Bank's loans to certain industry sectors that are likely to be most impacted by the COVID-19 outbreak and therefore deemed higher risk. These industry sectors include retail, restaurants, hotels, fitness center and churches, As of June 30, 2020, the Bank had $39.62 million of outstanding loans to these industry sectors, representing 7.73% of loans held-for-investment (or 9.72% of loans held-for-investment excluding PPP loans). Loan deferrals were $21.36 million or 53.90% of outstanding loans to borrowers in these higher risk industry sectors.

Following an assessment of the collectability of the loans held-for-investment at the end of the second quarter, it was determined that a provision for loan losses of $705,000 was necessary to account for loan charge offs, loan growth as well as the deteriorating macro-economic outlook because of the COVID-19 outbreak. The Bank booked a provision of $549,000 in the first quarter of 2020. The Bank's ALLL ratio was 1.02% of loans held-for-investment (or 1.28% of loans held-for investment excluding PPP loans) as of June 30, 2020 compared to an ALLL ratio of 1.16% at March 31, 2020.

Total Assets

Total assets at June 30, 2020 were $697.75 million compared to $536.29 million on March 31, 2020. Changes in major asset categories during linked quarters were as follows:

Cash balances and deposits with other banks increased by $16.77 million, while available-for-sale securities increased by $31.32 million.
Loans held-for-investment increased by $111.33 million, including PPP loan growth of $104.59 million and $6.74 million of other loans.

Total Liabilities

Total liabilities at June 30, 2020 were $630.20 million compared to total liabilities of $471.02 million on March 31, 2020. Total deposits were $487.90 million compared to total deposits of $412.68 million on March 31, 2020. On a linked quarter basis, interest bearing demand deposits increased by $14.65 million, with the bulk of the increase occurring in low cost interest checking and money market balances, while time deposits declined by $9.36 million. Non-interest bearing demand deposits increased during the quarter as well to $153.84 million, and comprised 31.53% of total deposits at the end of the quarter, compared to 20.58% of total deposits on March 31, 2020. The change in funding mix enables the Bank's cost of funds to benefit from lower interest rates. Federal Home Loan Bank advances declined by $21.50 million during the quarter, while the Bank added $104.69 million in PPP Liquidity Facility term advances to fund PPP loans.

Stockholders' Equity and Capital

Stockholders' equity at June 30, 2020 was $67.55 million compared to $65.27 million on March 31, 2020. Additional paid in capital at June 30, 2020 was $58.75 million on June 30, 2020 compared to $58.65 million on March 31, 2020. Accumulated Other Comprehensive Income ("AOCI"), which generally comprises unrealized gains and losses on available-for-sale securities on the balance sheet, increased by $655,273 on unrealized gains during the second quarter of 2020. Total shares issued and outstanding were 7,238,751 on June 30, 2020 compared to 7,238,751 shares on March 31, 2020, and 7,122,102 shares on June 30, 2019. The tangible book value of the Bank's common stock at June 30, 2020 was $9.33 per share compared to $9.02 per share on March 31, 2020 and $8.60 per share on June 30, 2019.

As of June 30, 2020 of the Bank's capital ratios were well above regulatory minimum capital ratios for well-capitalized banks. The Bank's capital ratios on June 30, 2020 and December 31, 2019 were as follows:

June 30, 2020 December 31, 2019

Total Capital Ratio 14.99% 16.24%

Tier 1 Capital Ratio 13.90% 15.26%

Common Equity

Tier 1 Capital Ratio 13.90% 15.26%

Leverage Ratio 11.23% 12.80%

About Freedom Bank

Freedom Bank is a community-oriented bank with locations in Fairfax, Reston, Chantilly and Vienna, Virginia. Freedom Bank also has a mortgage division headquartered in Chantilly. For information about Freedom Bank's deposit and loan services, visit the Bank's website at www.freedom.bank

Forward Looking Statements

This release contains forward-looking statements, including our expectations with respect to future events that are subject to various risks and uncertainties. Factors that could cause actual results to differ materially from management's projections, forecasts, estimates and expectations include: fluctuation in market rates of interest and loan and deposit pricing; general economic and financial market conditions, in the United States generally and particularly in the markets in which the Bank operates and which its loans are concentrated, including the effects of declines in real estate values, an increase in unemployment levels and slowdowns in economic growth, including as a result of COVID-19; maintenance and development of well-established and valued client relationships and referral source relationships; the adequacy or inadequacy of our allowance for loan and lease losses; acquisition or loss of key production personnel; and the potential adverse effects of unusual and infrequently occurring events, such as weather-related disasters, terrorist acts or public health events (such as COVID-19), and of governmental and societal responses thereto; these potential adverse effects may include, without limitation, adverse effects on the ability of the Bank's borrowers to satisfy their obligations to the Bank, on the value of collateral securing loans, on the demand for the Bank's loans or its other products and services, on incidents of cyberattack and fraud, on the Bank's liquidity or capital positions, on risks posed by reliance on third-party service providers, on other aspects of the Bank's business operations and on financial markets and economic growth. The Bank cautions readers that the list of factors above is not exclusive. The forward-looking statements are made as of the date of this release, and the Bank may not undertake steps to update the forward-looking statements to reflect the impact of any circumstances or events that arise after the date the forward-looking statements are made. In addition, our past results of operations are not necessarily indicative of future performance. Some of the financial tables in this document reflect classifications to accounts to improve consistency in financial reporting.

Contact:

Joseph J. Thomas
President & Chief Executive Officer
703-667-4161: Phone
jthomas@freedom.bank: Email

THE FREEDOM BANK OF VIRGINIA
 

CONSOLIDATED BALANCE SHEETS
 

 

 
 
 
 
 
 
 
 
 
 
 
 

 

 
(Unaudited)
 
 
(Unaudited)
 
 
(Audited)
 
 
(Unaudited)
 

 

 
June 30,
 
 
March 31,
 
 
December 31,
 
 
June 30,
 

 

 
2020
 
 
2020
 
 
2019
 
 
2019
 

ASSETS

 
 
 
 
 
 
 
 
 
 
 
 

Cash and Due from Banks

 
$
1,933,951
 
 
$
3,095,339
 
 
$
927,322
 
 
$
1,501,117
 

Interest Bearing Deposits with Banks

 
 
36,218,802
 
 
 
18,287,112
 
 
 
24,735,085
 
 
 
17,636,061
 

Securities Available-for-Sale

 
 
88,728,158
 
 
 
57,411,258
 
 
 
49,854,912
 
 
 
46,997,846
 

Restricted Stock Investments

 
 
3,601,050
 
 
 
4,514,750
 
 
 
3,752,750
 
 
 
3,277,800
 

Loans Held for Sale

 
 
31,891,370
 
 
 
29,539,880
 
 
 
11,656,802
 
 
 
14,094,057
 

PPP Loans Held for Investment

 
 
104,586,120
 
 
 

 
 
 

 
 
 

 

Other Loans Held for Investment

 
 
409,237,515
 
 
 
402,438,641
 
 
 
392,941,874
 
 
 
389,069,949
 

Allowance for Loan Losses

 
 
(5,225,692
)
 
 
(4,670,692
)
 
 
(4,121,693
)
 
 
(4,435,737
)

Net Loans

 
 
508,597,942
 
 
 
397,767,949
 
 
 
388,820,181
 
 
 
384,634,212
 

Bank Premises and Equipment, net

 
 
1,387,197
 
 
 
1,413,622
 
 
 
1,480,535
 
 
 
1,618,940
 

Accrued Interest Receivable

 
 
2,433,838
 
 
 
1,346,501
 
 
 
1,278,037
 
 
 
1,368,964
 

Deferred Tax Asset

 
 
858,030
 
 
 
678,826
 
 
 
857,698
 
 
 
864,642
 

Bank-Owned Life Insurance

 
 
17,013,098
 
 
 
16,885,603
 
 
 
12,783,605
 
 
 
12,589,855
 

Right of Use Asset, net

 
 
3,113,817
 
 
 
3,254,731
 
 
 
2,928,546
 
 
 
3,343,401
 

Other Assets

 
 
1,418,876
 
 
 
1,466,561
 
 
 
1,317,201
 
 
 
2,843,378
 

Total Assets

 
$
697,748,977
 
 
$
536,289,808
 
 
$
500,392,674
 
 
$
489,905,630
 

LIABILITIES AND STOCKHOLDERS' EQUITY

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Liabilities

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Deposits

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Demand Deposits

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Non-interest Bearing

 
$
153,835,083
 
 
$
84,937,943
 
 
$
80,630,053
 
 
$
81,750,368
 

Interest Bearing

 
 
150,476,495
 
 
 
135,821,899
 
 
 
112,605,618
 
 
 
112,197,896
 

Savings Deposits

 
 
3,295,441
 
 
 
2,275,796
 
 
 
2,153,939
 
 
 
2,544,341
 

Time Deposits

 
 
180,291,039
 
 
 
189,646,824
 
 
 
199,821,006
 
 
 
201,914,936
 

Total Deposits

 
 
487,898,058
 
 
 
412,682,462
 
 
 
395,210,616
 
 
 
398,407,541
 

Federal Home Loan Bank Advances

 
 
31,214,286
 
 
 
52,714,286
 
 
 
35,857,143
 
 
 
24,850,000
 

PPP Liquidity Facility Advances

 
 
104,687,489
 
 
 

 
 
 

 
 
 

 

Accrued Interest Payable

 
 
339,766
 
 
 
358,717
 
 
 
433,586
 
 
 
630,123
 

Lease Liability

 
 
3,182,552
 
 
 
3,314,889
 
 
 
2,981,132
 
 
 
3,372,738
 

Other Liabilities

 
 
2,874,217
 
 
 
1,951,421
 
 
 
1,883,782
 
 
 
1,395,681
 

Total Liabilities

 
 
630,196,367
 
 
 
471,021,775
 
 
 
436,366,259
 
 
 
428,656,083
 

Stockholders' Equity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Preferred stock, $0.01 par value, 5,000,000 shares authorized;

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

0 Shares Issued and Outstanding, 2020 and 2019

 
 

 
 
 

 
 
 

 
 
 

 

Common Stock, $0.01 Par Value, 25,000,000 Shares:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

23,000,000 Shares Voting and 2,000,000 Shares Non-voting.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Voting Common Stock:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

6,565,751, 6,565,751, 6,548,046 and 6,449,102 Shares Issued and Outstanding

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

at June 30, 2020, March 31, 2020, December 31, 2019 and June 30, 2019, respectively

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

(Includes 118,335, 118,335, 120,500 and 120,500 Unvested Shares at June 30, 2020

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

March 31, 2020, December 31, 2019 and June 30, 2019, respectively)

 
 
64,474
 
 
 
64,474
 
 
 
64,275
 
 
 
63,236
 

Non-Voting Common Stock:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

673,000 Shares Issued and Outstanding June 30, 2020, March 31, 2020

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

December 31, 2019 and June 30, 2019

 
 
6,730
 
 
 
6,730
 
 
 
6,730
 
 
 
6,730
 

Additional Paid-in Capital

 
 
58,751,910
 
 
 
58,648,131
 
 
 
58,526,913
 
 
 
57,655,145
 

Accumulated Other Comprehensive Income (Loss), Net

 
 
896,393
 
 
 
241,120
 
 
 
(29,274
)
 
 
(253,180
)

Retained Earnings

 
 
7,833,103
 
 
 
6,307,578
 
 
 
5,457,771
 
 
 
3,777,616
 

Total Stockholders' Equity

 
 
67,552,610
 
 
 
65,268,033
 
 
 
64,026,415
 
 
 
61,249,547
 

Total Liabilities and Stockholders' Equity

 
$
697,748,977
 
 
$
536,289,808
 
 
$
500,392,674
 
 
$
489,905,630
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

THE FREEDOM BANK OF VIRGINIA
 

CONSOLIDATED STATEMENTS OF OPERATIONS
 

 

 
(Unaudited)
 
 
(Unaudited)
 
 
(Unaudited)
 
 
(Unaudited)
 

 

 
For the three
 
 
For the three
 
 
For the six
 
 
For the six
 

 

 
months ended
 
 
months ended
 
 
months ended
 
 
months ended
 

 

 
June 30, 2020
 
 
June 30, 2019
 
 
June 30, 2020
 
 
June 30, 2019
 

Interest Income

 
 
 
 
 
 
 
 
 
 
 
 

Interest and Fees on Loans

 
$
5,508,679
 
 
$
5,022,253
 
 
$
10,544,324
 
 
$
10,226,971
 

Interest on Investment Securities

 
 
500,293
 
 
 
381,352
 
 
 
858,235
 
 
 
748,369
 

Interest on Deposits with Other Banks

 
 
13,001
 
 
 
94,979
 
 
 
91,239
 
 
 
220,307
 

Total Interest Income

 
 
6,021,974
 
 
 
5,498,584
 
 
 
11,493,798
 
 
 
11,195,647
 

Interest Expense

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest on Deposits

 
 
1,095,532
 
 
 
1,606,953
 
 
 
2,491,491
 
 
 
3,108,273
 

Interest on Borrowings

 
 
208,765
 
 
 
120,696
 
 
 
366,284
 
 
 
207,829
 

Total Interest Expense

 
 
1,304,297
 
 
 
1,727,650
 
 
 
2,857,775
 
 
 
3,316,101
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net Interest Income

 
 
4,717,677
 
 
 
3,770,934
 
 
 
8,636,022
 
 
 
7,879,545
 

Provision for Loan Losses

 
 
(705,000
)
 
 

 
 
 
(1,254,000
)
 
 
(147,500
)

Net Interest Income After

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Provision for Loan Losses

 
 
4,012,677
 
 
 
3,770,934
 
 
 
7,382,022
 
 
 
7,732,045
 

Non-Interest Income

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mortgage Loan Gain-on-Sale and Fee Revenue

 
 
2,805,338
 
 
 
1,168,251
 
 
 
4,923,204
 
 
 
1,963,191
 

Service Charges and Other Income

 
 
333,917
 
 
 
32,462
 
 
 
460,492
 
 
 
74,893
 

Gain on Sale of Securities

 
 

 
 
 
103,034
 
 
 
25,608
 
 
 
105,722
 

Increase in Cash Surrender Value of Bank-

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

owned Life Insurance

 
 
127,496
 
 
 
96,324
 
 
 
229,494
 
 
 
188,539
 

Total Non-interest Income

 
 
3,266,751
 
 
 
1,400,071
 
 
 
5,638,799
 
 
 
2,332,344
 

Non-Interest Expenses

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Officer and Employee Compensation

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

and Benefits

 
 
3,488,369
 
 
 
2,711,905
 
 
 
6,689,090
 
 
 
5,644,898
 

Occupancy Expense

 
 
300,634
 
 
 
288,213
 
 
 
593,428
 
 
 
563,989
 

Equipment and Depreciation Expense

 
 
147,910
 
 
 
227,717
 
 
 
331,932
 
 
 
413,238
 

Insurance Expense

 
 
51,263
 
 
 
77,984
 
 
 
103,597
 
 
 
155,968
 

Professional Fees

 
 
325,545
 
 
 
225,119
 
 
 
606,941
 
 
 
529,667
 

Data and Item Processing

 
 
285,942
 
 
 
187,073
 
 
 
460,076
 
 
 
415,574
 

Advertising

 
 
36,732
 
 
 
124,276
 
 
 
95,535
 
 
 
159,545
 

Franchise Taxes and State Assessment Fees

 
 
178,812
 
 
 
117,477
 
 
 
354,682
 
 
 
278,174
 

Mortgage Fees and Settlements

 
 
454,866
 
 
 
198,771
 
 
 
676,240
 
 
 
330,653
 

Other Operating Expense

 
 
156,734
 
 
 
235,124
 
 
 
305,222
 
 
 
418,097
 

Total Non-interest Expenses

 
 
5,426,806
 
 
 
4,393,660
 
 
 
10,216,744
 
 
 
8,909,803
 

Income Before Income Taxes

 
 
1,852,622
 
 
 
629,844
 
 
 
2,804,077
 
 
 
1,154,587
 

Income Tax Expense

 
 
327,097
 
 
 
120,769
 
 
 
428,746
 
 
 
129,525
 

Net Income

 
$
1,525,525
 
 
$
509,075
 
 
$
2,375,331
 
 
$
1,025,062
 

Earnings per Common Share – Basic

 
$
0.21
 
 
$
0.07
 
 
$
0.33
 
 
$
0.14
 

Earnings per Common Share – Diluted

 
$
0.21
 
 
$
0.07
 
 
$
0.33
 
 
$
0.14
 

Weighted-Average Common Shares

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Outstanding – Basic

 
 
7,238,751
 
 
 
7,114,190
 
 
 
7,233,136
 
 
 
7,102,226
 

Weighted-Average Common Shares

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Outstanding – Diluted

 
 
7,267,773
 
 
 
7,177,984
 
 
 
7,294,600
 
 
 
7,163,661
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
0.82
%
 
 
0.43
%

 

 
 
 
 
 
 
 
 
 
 
7.28
%
 
 
3.44
%

 

 
 
 
 
 
 
 
 
 
 
71.57
%
 
 
87.25
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

THE FREEDOM BANK OF VIRGINIA
 

CONSOLIDATED STATEMENTS OF OPERATIONS
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
For the three
 
 
For the three
 
 
For the three
 
 
For the three
 
 
For the three
 

 

 
months
ended
 
 
months
ended
 
 
months
ended
 
 
months
ended
 
 
months ended
 

 

 
June 30,
2020
 
 
March 31,
2020
 
 
December 31, 2019
 
 
September 30, 2019
 
 
June 30, 2019
 

Interest Income

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest and Fees on Loans

 
$
5,508,679
 
 
$
5,035,645
 
 
$
5,345,417
 
 
$
5,541,462
 
 
$
5,022,252
 

Interest on Investment Securities

 
 
500,293
 
 
 
357,942
 
 
 
278,164
 
 
 
343,288
 
 
 
381,352
 

Interest on Deposits with Other Banks

 
 
13,001
 
 
 
78,237
 
 
 
88,239
 
 
 
82,831
 
 
 
94,979
 

Total Interest Income

 
 
6,021,974
 
 
 
5,471,824
 
 
 
5,711,820
 
 
 
5,967,581
 
 
 
5,498,583
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest Expense

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest on Deposits

 
 
1,095,532
 
 
 
1,395,959
 
 
 
1,513,662
 
 
 
1,585,209
 
 
 
1,606,953
 

Interest on Borrowings

 
 
208,765
 
 
 
157,519
 
 
 
162,502
 
 
 
174,810
 
 
 
120,696
 

Total Interest Expense

 
 
1,304,297
 
 
 
1,553,478
 
 
 
1,676,164
 
 
 
1,760,019
 
 
 
1,727,649
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net Interest Income

 
 
4,717,677
 
 
 
3,918,346
 
 
 
4,035,657
 
 
 
4,207,562
 
 
 
3,770,934
 

Provision for Loan Losses

 
 
(705,000
)
 
 
(549,000
)
 
 

 
 
 
(47,000
)
 
 
(147,500
)

Net Interest Income after

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Provision for Loan Losses

 
 
4,012,677
 
 
 
3,369,346
 
 
 
4,035,657
 
 
 
4,160,562
 
 
 
3,623,434
 

Non-Interest Income

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gain on Sale of Mortgage Loans

 
 
2,805,338
 
 
 
1,886,952
 
 
 
924,410
 
 
 
1,473,453
 
 
 
997,461
 

Service Charges and Other Income

 
 
333,917
 
 
 
357,489
 
 
 
218,583
 
 
 
265,589
 
 
 
203,252
 

Gains on Sale of Securities

 
 

 
 
 
25,608
 
 
 

 
 
 

 
 
 
103,034
 

Increase in Cash Surrender Value of Bank-

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

owned Life Insurance

 
 
127,496
 
 
 
101,998
 
 
 
96,727
 
 
 
97,022
 
 
 
96,324
 

Total Non-interest Income

 
 
3,266,751
 
 
 
2,372,048
 
 
 
1,239,720
 
 
 
1,836,064
 
 
 
1,400,071
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Non-Interest Expenses

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Officer and Employee Compensation

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

and Benefits

 
 
3,488,369
 
 
 
3,200,721
 
 
 
2,637,977
 
 
 
3,064,244
 
 
 
2,711,906
 

Occupancy Expense

 
 
300,634
 
 
 
292,794
 
 
 
293,058
 
 
 
285,798
 
 
 
288,213
 

Equipment and Depreciation Expense

 
 
147,910
 
 
 
184,022
 
 
 
261,871
 
 
 
216,275
 
 
 
227,717
 

Insurance Expense

 
 
51,263
 
 
 
52,335
 
 
 
10,760
 
 
 
(48,502
)
 
 
77,984
 

Professional Fees

 
 
325,545
 
 
 
281,396
 
 
 
278,594
 
 
 
297,947
 
 
 
225,119
 

Data and Item Processing

 
 
285,942
 
 
 
174,135
 
 
 
178,416
 
 
 
245,178
 
 
 
174,656
 

Advertising

 
 
36,732
 
 
 
58,804
 
 
 
113,194
 
 
 
63,543
 
 
 
124,276
 

Franchise Taxes and State Assessment Fees

 
 
178,812
 
 
 
175,870
 
 
 
175,920
 
 
 
175,895
 
 
 
117,478
 

Mortgage Fees and Settlements

 
 
454,866
 
 
 
221,374
 
 
 
200,192
 
 
 
312,346
 
 
 
198,771
 

Other Operating Expense

 
 
156,734
 
 
 
148,487
 
 
 
181,005
 
 
 
306,439
 
 
 
247,541
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Total Non-interest Expenses

 
 
5,426,806
 
 
 
4,789,937
 
 
 
4,330,987
 
 
 
4,919,163
 
 
 
4,393,661
 

Income before Income Taxes

 
 
1,852,622
 
 
 
951,455
 
 
 
944,389
 
 
 
1,077,463
 
 
 
629,844
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Income Tax Expense

 
 
327,097
 
 
 
101,649
 
 
 
196,581
 
 
 
145,115
 
 
 
120,769
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net Income

 
$
1,525,525
 
 
$
849,806
 
 
$
747,808
 
 
$
932,348
 
 
$
509,075
 

Earnings per Common Share – Basic

 
$
0.21
 
 
$
0.12
 
 
$
0.10
 
 
$
0.13
 
 
$
0.07
 

Earnings per Common Share – Diluted

 
$
0.21
 
 
$
0.11
 
 
$
0.10
 
 
$
0.13
 
 
$
0.07
 

Weighted-Average Common Shares

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Outstanding – Basic

 
 
7,238,751
 
 
 
7,348,022
 
 
 
7,212,568
 
 
 
7,150,649
 
 
 
7,114,190
 

Weighted-Average Common Shares

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Outstanding – Diluted

 
 
7,267,773
 
 
 
7,435,490
 
 
 
7,272,228
 
 
 
7,194,786
 
 
 
7,177,984
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Average Balances, Income and Expenses, Yields and Rates

(Unaudited)

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
Three Months Ended
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
 
 

 

 
June 30,
2020
 
 
 
 
 
 
 
 
March 31,
2020
 
 
 
 
 
 
 

 

 
Average Balance
 
 
Income/Expense
 
 
Yield
 
 
Average Balance
 
 
Income/Expense
 
 
Yield
 

Assets

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cash

 
$
59,558,556
 
 
$
13,001
 
 
 
0.09
%
 
$
24,919,112
 
 
$
78,237
 
 
 
1.26
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Investments (Tax Exempt)

 
 
5,953,752
 
 
 
48,657
 
 
 
 
 
 
 
4,541,049
 
 
 
38,411
 
 
 
 
 

Investments (Taxable)

 
 
65,890,906
 
 
$
399,846
 
 
 
 
 
 
 
51,701,396
 
 
 
327,597
 
 
 
 
 

Total Investments

 
 
71,844,658
 
 
 
448,504
 
 
 
2.51
%
 
 
56,242,445
 
 
 
366,008
 
 
 
2.62
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Loans (Tax Exempt)

 
 
4,523,295
 
 
 
60,064
 
 
 
 
 
 
 
4,533,284
 
 
 
60,196
 
 
 
 
 

Loans (Taxable)

 
 
506,239,897
 
 
 
5,461,229
 
 
 
 
 
 
 
400,285,264
 
 
 
4,988,089
 
 
 
 
 

Total Loans

 
 
510,763,192
 
 
 
5,521,293
 
 
 
4.35
%
 
 
404,818,548
 
 
 
5,048,285
 
 
 
5.02
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Earning Assets

 
 
642,166,406
 
 
 
5,982,798
 
 
 
3.75
%
 
 
485,980,105
 
 
 
5,492,530
 
 
 
4.55
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Assets

 
$
665,767,229
 
 
 
 
 
 
 
 
 
 
$
504,847,678
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Liabilities

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest Checking

 
$
23,143,536
 
 
 
13,029
 
 
 
0.23
%
 
$
25,788,577
 
 
 
22,351
 
 
 
0.35
%

Money Market

 
 
129,569,263
 
 
 
139,111
 
 
 
0.43
%
 
 
94,433,574
 
 
 
275,134
 
 
 
1.17
%

Savings

 
 
2,533,676
 
 
 
703
 
 
 
0.11
%
 
 
2,382,236
 
 
 
1,099
 
 
 
0.19
%

Time Deposits

 
 
183,220,441
 
 
 
942,690
 
 
 
2.07
%
 
 
195,524,566
 
 
 
1,097,375
 
 
 
2.26
%

Interest Bearing Deposits

 
 
338,466,915
 
 
 
1,095,532
 
 
 
1.30
%
 
 
318,128,953
 
 
 
1,395,959
 
 
 
1.76
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Borrowings

 
$
110,132,851
 
 
 
208,765
 
 
 
0.76
%
 
$
40,076,102
 
 
 
157,519
 
 
 
1.58
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest Bearing Liabilities

 
 
448,599,766
 
 
 
1,304,297
 
 
 
1.17
%
 
 
358,205,055
 
 
 
1,553,478
 
 
 
1.74
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Non Interest Bearing Deposits

 
$
145,370,721
 
 
 
 
 
 
 
 
 
 
$
76,609,290
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cost of Funds

 
 
 
 
 
 
 
 
 
 
0.88
%
 
 
 
 
 
 
 
 
 
 
1.44
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net Interest Margin1

 
 
 
 
 
$
4,678,501
 
 
 
2.93
%
 
 
 
 
 
$
3,939,052
 
 
 
3.26
%

Shareholders Equity

 
$
66,403,194
 
 
 
 
 
 
 
 
 
 
$
64,868,539
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

1 Net interest margin is calculated as fully taxable equivalent net interest income divided by average earning assets and represents the Bank's net yield on its earning assets
 

 

Average Balances, Income and Expenses, Yields and Rates

(Unaudited)

 

 
Three Months Ended
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
 
 
 
Six Months Ended
 
 
 
 
 
 
 
 
Six Months Ended
 
 
 
 
 
 
 

 

 
June 30, 2020
 
 
Income /
 
 
 
 
 
June 30, 2019
 
 
Income /
 
 
 
 
 
June 30, 2020
 
 
Income /
 
 
 
 
 
June 30, 2019
 
 
Income /
 
 
 
 

 

 
Average Balance
 
 
Expense
 
 
Yield
 
 
Average Balance
 
 
Expense
 
 
Yield
 
 
Average Balance
 
 
Expense
 
 
Yield
 
 
Average Balance
 
 
Expense
 
 
Yield
 

Assets

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cash

 
$
59,558,556
 
 
$
13,001
 
 
 
0.09
%
 
$
19,212,889
 
 
$
94,979
 
 
 
1.98
%
 
$
42,238,834
 
 
$
91,238
 
 
 
0.43
%
 
$
19,955,536
 
 
$
220,307
 
 
 
2.23
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Investments (Tax Exempt)

 
 
5,953,752
 
 
 
48,657
 
 
 
 
 
 
 
4,380,278
 
 
 
38,468
 
 
 
 
 
 
 
5,247,401
 
 
 
87,069
 
 
 
 
 
 
 
4,511,188
 
 
 
81,586
 
 
 
 
 

Investments (Taxable)

 
 
65,890,906
 
 
 
399,846
 
 
 
 
 
 
 
51,397,468
 
 
 
350,962
 
 
 
 
 
 
 
58,796,151
 
 
 
789,451
 
 
 
 
 
 
 
50,359,121
 
 
 
683,916
 
 
 
 
 

Total Investments

 
 
71,844,658
 
 
 
448,504
 
 
 
2.51
%
 
 
55,777,746
 
 
 
389,430
 
 
 
2.80
%
 
 
64,043,552
 
 
 
876,520
 
 
 
2.75
%
 
 
54,870,309
 
 
 
765,502
 
 
 
2.81
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Loans (Tax Exempt)

 
 
4,523,295
 
 
 
60,064
 
 
 
 
 
 
 
4,618,618
 
 
 
61,329
 
 
 
 
 
 
 
4,528,289
 
 
 
120,261
 
 
 
 
 
 
 
2,629,441
 
 
 
73,514
 
 
 
 
 

Loans (Taxable)

 
 
506,239,897
 
 
 
5,461,229
 
 
 
 
 
 
 
385,967,638
 
 
 
4,973,795
 
 
 
 
 
 
 
453,262,580
 
 
 
10,449,318
 
 
 
 
 
 
 
387,344,493
 
 
 
10,168,887
 
 
 
 
 

Total Loans

 
 
510,763,192
 
 
 
5,521,293
 
 
 
4.35
%
 
 
390,586,256
 
 
 
5,035,124
 
 
 
5.17
%
 
 
457,790,870
 
 
 
10,569,579
 
 
 
4.64
%
 
 
389,973,934
 
 
 
10,242,401
 
 
 
5.30
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Earning Assets

 
 
642,166,406
 
 
 
5,982,798
 
 
 
3.75
%
 
 
465,576,891
 
 
 
5,519,533
 
 
 
4.76
%
 
 
564,073,255
 
 
 
11,537,337
 
 
 
4.11
%
 
 
464,799,779
 
 
 
11,228,210
 
 
 
4.87
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Assets

 
$
665,767,229
 
 
 
 
 
 
 
 
 
 
$
483,716,025
 
 
 
 
 
 
 
 
 
 
$
585,307,453
 
 
 
 
 
 
 
 
 
 
$
483,113,230
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Liabilities

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest Checking

 
$
23,143,536
 
 
 
13,029
 
 
 
0.23
%
 
$
7,006,451
 
 
 
9,307
 
 
 
0.53
%
 
$
22,817,658
 
 
 
30,066
 
 
 
0.26
%
 
$
6,970,274
 
 
 
18,472
 
 
 
0.53
%

Money Market

 
 
129,569,263
 
 
 
139,111
 
 
 
0.43
%
 
 
108,817,738
 
 
 
386,793
 
 
 
1.43
%
 
 
113,649,817
 
 
 
419,559
 
 
 
0.74
%
 
 
112,815,492
 
 
 
782,032
 
 
 
1.40
%

Savings

 
 
2,533,676
 
 
 
703
 
 
 
0.11
%
 
 
2,411,698
 
 
 
1,202
 
 
 
0.20
%
 
 
2,457,956
 
 
 
1,802
 
 
 
0.15
%
 
 
2,650,850
 
 
 
2,613
 
 
 
0.20
%

Time Deposits

 
 
183,220,441
 
 
 
942,690
 
 
 
2.07
%
 
 
201,531,076
 
 
 
1,209,651
 
 
 
2.38
%
 
 
189,372,476
 
 
 
2,040,065
 
 
 
2.17
%
 
 
200,562,733
 
 
 
2,305,153
 
 
 
2.32
%

Interest Bearing Deposits

 
 
338,466,915
 
 
 
1,095,532
 
 
 
1.30
%
 
 
319,766,963
 
 
 
1,606,953
 
 
 
2.02
%
 
 
328,297,907
 
 
 
2,491,492
 
 
 
1.53
%
 
 
322,999,349
 
 
 
3,108,270
 
 
 
1.94
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Borrowings

 
 
110,132,851
 
 
 
208,765
 
 
 
0.76
%
 
 
21,830,769
 
 
 
120,696
 
 
 
2.22
%
 
 
75,104,477
 
 
$
366,284
 
 
 
0.98
%
 
 
19,494,238
 
 
 
207,827
 
 
 
2.15
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest Bearing Liabilities

 
 
448,599,766
 
 
 
1,304,297
 
 
 
1.17
%
 
 
341,597,732
 
 
 
1,727,649
 
 
 
2.03
%
 
 
403,402,384
 
 
 
2,857,775
 
 
 
1.42
%
 
 
342,493,587
 
 
 
3,316,097
 
 
 
1.95
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Non Interest Bearing Deposits

 
$
145,370,721
 
 
 
 
 
 
 
 
 
 
$
76,077,226
 
 
 
 
 
 
 
 
 
 
$
110,990,006
 
 
 
 
 
 
 
 
 
 
$
75,114,731
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cost of Funds

 
 
 
 
 
 
 
 
 
 
0.88
%
 
 
 
 
 
 
 
 
 
 
1.66
%
 
 
 
 
 
 
 
 
 
 
1.12
%
 
 
 
 
 
 
 
 
 
 
1.60
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net Interest Margin1

 
 
 
 
 
$
4,678,501
 
 
 
2.93
%
 
 
 
 
 
$
3,791,884
 
 
 
3.27
%
 
 
 
 
 
$
8,679,562
 
 
 
3.09
%
 
 
 
 
 
$
7,912,113
 
 
 
3.43
%

Shareholders Equity

 
$
66,403,194
 
 
 
 
 
 
 
 
 
 
$
60,715,800
 
 
 
 
 
 
 
 
 
 
$
65,635,866
 
 
 
 
 
 
 
 
 
 
$
60,146,734
 
 
 
 
 
 
 
 
 

ROAA

 
 
0.92
%
 
 
 
 
 
 
 
 
 
 
0.42
%
 
 
 
 
 
 
 
 
 
 
0.82
%
 
 
 
 
 
 
 
 
 
 
0.43
%
 
 
 
 
 
 
 
 

ROAE

 
 
9.24
%
 
 
 
 
 
 
 
 
 
 
3.36
%
 
 
 
 
 
 
 
 
 
 
7.28
%
 
 
 
 
 
 
 
 
 
 
3.44
%
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

1 Net interest margin is calculated as fully taxable equivalent net interest income divided by average earning assets and represents the Bank's net yield on its earning assets
 

 

Selected Financial Data by Quarter Ended:               

(Unaudited)                

Balance Sheet Ratios

 
June 30, 2020
 
 
March 31, 2020
 
 
December 31, 2019
 
 
September 30, 2019
 
 
June 30, 2019
 

Loans to Deposits

 
 
111.85
%
 
 
104.68
%
 
 
102.38
%
 
 
105.93
%
 
 
101.19
%

Income Statement Ratios (Quarterly)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Return on Average Assets (ROAA)

 
 
0.92
%
 
 
0.68
%
 
 
0.59
%
 
 
0.75
%
 
 
0.42
%

Return on Average Equity (ROAE)

 
 
9.24
%
 
 
5.27
%
 
 
4.66
%
 
 
6.34
%
 
 
3.36
%

Efficiency Ratio

 
 
67.97
%
 
 
76.15
%
 
 
82.10
%
 
 
81.39
%
 
 
84.97
%

Net Interest Margin1

 
 
2.93
%
 
 
3.26
%
 
 
3.33
%
 
 
3.52
%
 
 
3.27
%

Yield on Average Earning Assets

 
 
3.75
%
 
 
4.55
%
 
 
4.71
%
 
 
4.99
%
 
 
4.76
%

Yield on Securities

 
 
2.51
%
 
 
2.62
%
 
 
2.32
%
 
 
2.79
%
 
 
2.80
%

Yield on Loans

 
 
4.35
%
 
 
5.02
%
 
 
5.20
%
 
 
5.36
%
 
 
5.17
%

Cost of Funds

 
 
0.88
%
 
 
1.44
%
 
 
1.54
%
 
 
1.64
%
 
 
1.66
%

Noninterest income to Total Revenue

 
 
40.91
%
 
 
37.71
%
 
 
23.50
%
 
 
30.38
%
 
 
27.08
%

Per Share Data

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Tangible Book Value

 

9.33
 
 

9.02
 
 

8.86
 
 

8.76
 
 

8.60
 

Share Price Data

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Closing Price

 

7.50
 
 

5.80
 
 

10.45
 
 

9.95
 
 

9.98
 

Book Value Multiple

 
 
79
%
 
 
64
%
 
 
118
%
 
 
114
%
 
 
116
%

Common Stock Data

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Outstanding Shares at End of Period

 
 
7,238,751
 
 
 
7,238,751
 
 
 
7,221,046
 
 
 
7,211,046
 
 
 
7,122,102
 

Weighted Average shares outstanding, basic

 
 
7,238,751
 
 
 
7,348,022
 
 
 
7,212,568
 
 
 
7,150,649
 
 
 
7,114,190
 

Weighted Average shares outstanding, diluted

 
 
7,267,773
 
 
 
7,435,490
 
 
 
7,272,228
 
 
 
7,194,786
 
 
 
7,177,984
 

Capital Ratios

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Tier 1 Leverage ratio

 
 
11.23
%
 
 
12.88
%
 
 
12.80
%
 
 
12.80
%
 
 
12.71
%

Common Equity Tier 1 ratio

 
 
13.90
%
 
 
14.35
%
 
 
15.26
%
 
 
14.79
%
 
 
14.91
%

Tier 1 Risk Based Capital ratio

 
 
13.90
%
 
 
14.35
%
 
 
15.26
%
 
 
14.79
%
 
 
14.91
%

Total Risk Based Capital ratio

 
 
14.99
%
 
 
15.38
%
 
 
16.24
%
 
 
15.84
%
 
 
15.98
%

Credit Quality

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net Charge-offs to Average Loans

 
 
0.02
%
 
 
0.00
%
 
 
0.09
%
 
 
0.00
%
 
 
0.06
%

Total Non-performing Loans to Total Loans

 
 
0.73
%
 
 
0.53
%
 
 
1.54
%
 
 
0.67
%
 
 
0.79
%

Total Non-performing Assets to Total Assets

 
 
0.57
%
 
 
0.43
%
 
 
1.24
%
 
 
0.55
%
 
 
0.65
%

Nonaccrual Loans to Total Loans

 
 
0.71
%
 
 
0.50
%
 
 
0.42
%
 
 
0.53
%
 
 
0.76
%

Provision for Loan and Lease Losses

 

705,000
 
 

549,000
 
 

0
 
 

47,000
 
 

147,500
 

Allowance for Loan and Lease Losses to loans held-for-investment

 
 
1.02
%
 
 
1.16
%
 
 
1.05
%
 
 
1.12
%
 
 
1.14
%

Allowance for Loan and Lease Losses to loans held-for-investment (ex PPP loans)

 
 
1.28
%
 
 
1.16
%
 
 
1.05
%
 
 
1.12
%
 
 
1.14
%

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 

1 Net interest margin is calculated as fully taxable equivalent net interest income divided by average earning assets and represents the Bank's net yield on its earning assets

SOURCE: Freedom Bank of VA

ReleaseID: 599454

Capstone Turbine (Nasdaq:CPST) Continues to Diversify Into the Manufacturing Sector With an Order for a C800S & C65 From National Account Pure World Energy

15-Year Energy as a Service Project for a Food and Beverage Packaging Producer Adds to Pure World Energy's Existing 2.6 MW Capstone Fleet

VAN NUYS, CA / ACCESSWIRE / July 30, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that it received an order for a natural gas-fueled 800 kilowatt C800 Signature Series microturbine and C65 ICHP microturbine for a food and beverage packaging producer in the United Kingdom from Pure World Energy Limited (PWE) (www.pureworldenergycom). PWE, Capstone's national account energy service company, or ESCO partner, for the United Kingdom, secured the 15-year energy services agreement with the end-use customer in the manufacturing sector. The project is scheduled to be commissioned in January 2021.

Capstone recently divided its internal sales team into two separate sales organizations. One organization focused solely on developing and managing the existing worldwide distribution channel and one directly responsible for growing Capstone's national account business and long-term rental fleet.

"This new strategic organizational change is aimed at improving year-over-year revenue growth by expanding our current national account and OEM business, as well as building closer corporate ties to large, multinational customers to drive incremental direct sales opportunities," stated Mr. Jamison. "We have set an internal goal of deriving 15% of our annual product sales from this new direct sales organization with hopes that this percentage will increase in each subsequent year," added Mr. Jamison.

Detailed design and permitting of the new on-site power plant is currently underway with construction due to commence in October of this year. PWE will design, build, finance, operate, manage and maintain the new plant on an energy services contract basis, selling electricity and steam to the customer as part of their energy as a service model.

The Capstone microturbines will be deployed in a combined heat and power (CHP) application and will include a biomass steam generation unit in the state-of-the-art energy center. The microturbines will deliver 65% of the on-site electricity, while the steam boilers will provide all of the process steam for the food and beverage packaging facility. The microturbine systems are expected to yield the customer significant benefits and save over £100,000 per year in energy costs.

Already an environmentally-conscious industry leader, the customer partnered with PWE on a microturbine-powered CHP solution to further boost its energy efficiency goals and enable significant carbon footprint reductions and energy savings. CHP enables manufacturers to produce heat and electricity on-site at the source and can deliver a large majority of a plant's electricity and heat requirements. By producing electricity where it is consumed, rather than at a central power plant, there are no transmission losses. On-site power generation can, therefore, be up to 80% efficient.

"Pure World Energy is delighted to sign this 15-year ESCO contract on a CHP project with a company that is dedicated to reducing its carbon footprint," said Sean Fitzpatrick, CEO at Pure World Energy. "Capstone microturbines are central to our smart micro-grid strategy to help our customers achieve their energy efficiency, emissions reductions, and resiliency targets," concluded Mr. Fitzpatrick.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems, for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 599586

Wi2Wi Reaches Settlement with Twin Cities Fire Insurance

Not for Dissemination in the United States or to United States Newswire Services

TORONTO, ON / ACCESSWIRE / July 30, 2020 / Wi2Wi Corporation (TSXV:YTY)(OTC PINK:ISEYF) (Wi2Wi or the Company) announces that it has reached a confidential settlement with Twin Cities Fire Insurance in connection with payments made by the Company to a former executive pursuant to previously disclosed garnishment proceedings. No payment is to be made nor received by the Company in connection with the confidential settlement.

For further information, please contact:

Dawn Leeder
Chief Financial Officer
+1-608-203-0234
dawn_l@wi2wi.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Wi2Wi Corporation

Wi2Wi enables customers to substantially reduce their wireless R&D expenses and time to market. Wi2Wi designs, manufactures and markets deeply integrated, end-to-end wireless connectivity solutions as well as customizable, high- performance timing and frequency control devices. Wi2Wi provides real time technical support throughout the entire product life cycle for customers across the Internet of Things (IoT), Industrial Internet of Things (IIoT), Avionics, Space, Industrial, Medical and Government sectors.

Wi2Wi was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, Wisconsin. The branch office, located in Hyderabad, India, focuses on developing end to end wireless connectivity subsystems and solutions.

Wi2Wi has partnered with best-in-class global leaders in technology, manufacturing and sales. The company uses a global network of manufacturer's representatives to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales.

Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward- looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Wi2Wi Corporation

ReleaseID: 599530

Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

TORONTO, ON / ACCESSWIRE / July 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The company recently received expedited approval to begin the Phase 2/3 study in Canada and is seeking government grants to accelerate site selection and initiate patient enrollment.

EB05 is an experimental monoclonal antibody that the company believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome (ARDS) – the leading cause of death in COVID-19 patients. Specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling – an important mediator of inflammation responsible for acute lung injury that has been shown to be activated by SARS-CoV1 and Influenza viruses.

Based on previous clinical data and the mechanism of action, the company believes that modulating the TLR4 signaling pathway could reduce the number of ICU patients and decrease the need for mechanical ventilation, ultimately saving lives. The safety and tolerability of EB05 has been demonstrated in more than 120 subjects. The antibody therapy has demonstrated an ability to resolve fever as well as stabilize heart rates and breathing rates in test subjects who were injected with a potent inducer of acute systemic inflammation.

"The submission of the IND for EB05 in COVID-19 patients marks a key step in our plans to extend our planned Phase 2/3 study," said Dr. Par Nijhawan, Chief Executive Officer of Edesa. "We have received positive interest from key opinion leaders regarding our proposed clinical trial and are communicating with hospitals across the country regarding our protocol."

As planned, Edesa's Phase 2/3 study will be an adaptive, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EB05 in adult hospitalized patients who have or are at risk of developing ARDS. The company plans to enroll up to 450 patients in the first phase of the trial. Patients will be infused intravenously with a single dose of EB05 or placebo. Should the drug treatment demonstrate promising results at the Phase 2 readout, the protocol allows for enrollment to continue as a pivotal Phase 3 study. The newly filed IND application for the COVID-19 study supplements and references an existing approved IND for EB05.

About ARDS
Acute Respiratory Distress Syndrome is the leading cause of death in COVID-19 patients. The U.S. Centers for Disease Control (CDC) reports that 20% to 42% of hospitalized COVID-19 patients develop ARDS, which increases to 67% to 85% for patients admitted to the ICU. Mortality among patients admitted to the ICU ranges from 39% to 72% depending on the study and characteristics of patient population, according to the CDC. ARDS involves an exaggerated immune response leading to inflammation and injury to the lungs that results in edema that deprives the body of oxygen. For moderate to severe cases, there are currently few meaningful treatments, other than supplemental oxygen and mechanical ventilation, and patients suffer high mortality rates. In addition to virus-induced pneumonia, ARDS can be caused by smoke/chemical inhalation, sepsis, chest injury and other causes. Prior to COVID-19, ARDS accounted for 10% of intensive care unit admissions, representing more than 3 million patients globally each year. ARDS has historically affected approximately 200,000 patients each year in the United States, resulting in nearly 75,000 deaths annually.

About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. The company is developing late-stage monoclonal antibodies that block certain immune signaling proteins, known as TLR4 and CXCL10. These molecules are associated with a broad range of diseases, including the inflammation associated infectious diseases. Due to the global health emergency, Edesa has prioritized the development of EB05 as a potential treatment for moderate to severe COVID-19 patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts.

Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: the company's belief that EB05 could regulate the overactive immune response associated with ARDS, the company's belief that EB05 could modulate the TLR4 signaling pathway for the benefit of patients, and the company's plans regarding its Phase 2/3 study. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

CONTACT:
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

SOURCE: Edesa Biotech

ReleaseID: 599552

Pastry Fillings Market to Reflect Steady Growth at 5% CAGR Through 2030; Clean-label, Natural, and Organic Ingredients to Gain Significant Traction

Pastry filling manufacturers are extensively investing in creating a wide product portfolio, and optimizing supply chains to reduce the impact of volatile yields of essential ingredients in the industry.

ROCKVILLE, MD / ACCESSWIRE / July 30, 2020 / The global pastry fillings market is anticipated to display a healthy 5% CAGR between the 2020 to 2030 forecast period. According to Fact.MR, changes in consumer snacking habits will have a major influence on developments in the pastry fillings market. Pastry filling formulations are changing to emphasize more on nutrition, as consumers are increasingly aware about factors that could potentially impact health. On the other hand, the covid-19 pandemic is also opening doors to conventional pandemics, to increase shelf life, and aid in food security during the crisis period.

"Rising demand for pastry fillings formulations with bake stable characteristics is anticipated to display major growth owing to higher consumer interest in experimenting with unique flavors. Fruit flavors including banana, pomegranate, and cherry, are gaining interest and will influence industry developments in the months ahead," says the FACT.MR analyst.

Request a report sample to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4778

Pastry Fillings Market- Key Takeaways

Nut-based fillings are displaying rapid growth owing to superior texture, flavor, and nutritional characteristics.
Organic filling ingredients are steadily gaining market share, driven by changes in lifestyle trends among a wider range of consumer demographic.
Developed regions are witnessing higher demand for pastry fillings owing to high consumer bias towards a habit of frequent snacking.

Pastry Fillings Market- Driving Factors

Innovations in terms of natural ingredients, and low-calorie filling formulations contribute to market growth.
The growing influence of western culture and cuisine in Asian countries is a key driver to market growth.

Pastry Fillings Market- Major Restraints

Health concerns associated with consumption of sugary snacks, particularly among obese or diabetic people hinders adoption.
High costs, and volatile yields associated with natural and organic fillings hold back market growth.

COVID-19 Impact on Pastry fillings Market

The harsh economic impact of the coronavirus pandemic on the bakery industry, particularly the small -scale players had temporarily impacted the demand for pastry fillings. However, consistent demand for nutritional foods, and investments from the food processing industry are contributing to the production of a wider range of pastry filling formulations. The trend is expected to continue throughout and even after the end of the pandemic.

Explore the global Pastry fillings Market with 231 figures, 96 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4778/pastry-fillings-market

Competitive Landscape

Bakels Group, Puratos Group, EFCO Products, Dawn Food Products Inc., Amero Foods Mfg. Corp., Rich Products Corp., Barry Callebaut, Sokol and Co. Inc., Glazir d.o.o., and Pennant Ingredients Inc. are leading pastry filling manufacturers in the global market.

Pastry fillings market players are primarily interested in natural, and clean label ingredients in pastry filling formulations, to widen their portfolios and keep up with changing consumer demand.

For instance, Barry Callebaut has launched a new 100% natural, dark cocoa powder for bakery applications, including pastry fillings. Dawn Foods has set up its Balance Cleaner Ingredients initiative for products free from artificial ingredients, high fructose corn syrup, and hydrogenated oils. Puratos is providing fillings in the Vivafil and Topfil lines, comprising up to 90% of fruit ingredients.

About the Report

This study offers readers a comprehensive market forecast of the pastry fillings market. Global, regional and country-level analysis of the top industry trends impacting the pastry fillings market is covered in this FACT.MR study. The report offers insights on the pastry fillings market on the basis of type (jelly and creams), source (dairy and non-dairy), application (HoReCa, bakery & confectionary, and residential) flavor (unflavored, and flavored) and sales channel (direct sales and retail sales), across six regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and Middle East & Africa).

Explore FACT.MR's Comprehensive Coverage of Food & Beverages Landscape

Fat Replacer Market– Get the latest insights on the global fat replacer market through FACT.MR's report covering analysis for projection period (2018-2027).

Cannabidiol Market– FACT.MR's study on the global cannabidiol market covers trends, tech innovations, players, and strategies for 2017-2026.

Bromate Substitute Market– Obtain analysis on the global bromate substitute market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2019-2029.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the food & beverages sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1545/global-pastry-fillings-market

SOURCE: FactMR

ReleaseID: 599613

Sokoman Minerals Reports Discovery of High-Grade Boulders at South Pond, Moosehead Gold Project, Newfoundland

High-grade Eastern Trend-type boulders assay up to 157g/t Au and include enriched silver values up to 36.2 g/t Ag

ST. JOHN'S, NL / ACCESSWIRE / July 30, 2020 / Sokoman Minerals Corp. (TSXV:SIC)(OTCQB:SICNF) (the "Company" or "Sokoman") is pleased to announce that prospecting at South Pond, 400 metres along strike to the south west of the Eastern Trend zone, has located a cluster of angular quartz float with high-grade grab sample assay results ranging from 0.318 g/t Au to 157.04 g/t Au, as well as enriched silver values up to 36.2 g/t Ag.

Unusually low water levels allowed prospectors to locate angular quartz float (from 0.2 to 0.5 m maximum dimension) from the northern end of South Pond, near where previous operators found two clusters of mineralized float, which assayed from 0.20 to 1.03 g/t Au, and from 5.4 to 17.5 g/t Au. The newly discovered boulders were located in two clusters (East and West), on opposite sides of a bay, displaying different mineralogy and precious metal grades. The following table shows detailed Au results using a total pulp metallics process, with silver (Ag) and antimony (Sb) from the ICP analyses also shown. Antimony is a key pathfinder metal for high-grade mineralization at Moosehead and at the Fosterville deposit in Australia which is considered to be an analogue for Moosehead given its stratigraphic and structural setting.

The average grade of the East cluster samples is 36.59 g/t Au and 11.01 g/t Ag, while the West cluster samples averaged 1.91 g/t Au and 1.28 g/t Ag. Three (3) samples were noted to contain visible gold (VG) and coarse fraction analysis (+150 Mesh) of 11 of the 20 samples, produced results suggesting coarse gold may have been present based on assays ranging from 58,175 ppb Au in sample 361068, to 2,238,802 ppb Au in sample 361051 (weighted averages for all samples are shown).

The attached sample map uses a background of total field magnetics from the 2020 winter airborne survey with the samples overlain, as well as historical and Sokoman drilling shown. While some drilling has taken place in the vicinity of the new float samples, it is most likely that the float originated to the south of their present location based on perceived ice-flow movements and three anomalous (10 ppb Au), lake sediment values in South Pond. The lake sediment results in South Pond are very encouraging given that similar strength lake sediment samples were also obtained at North Pond, where the Eastern Trend gold zone is located.

The magnetics show several NE as well as north trending structures trending under South Pond that may be related to in-situ mineralization, where little to no drilling has taken place. Modeling of the magnetics will allow effective planning for diamond drilling in the area, a priority for drill testing in the upcoming Phase 6 program. In the immediate area, visible gold was reported from holes MH-01-07, MH-02-34, and MH-18-41, although Au gave only anomalous values, suggesting the high-grade mineralization exhibited by the new sampling has not been tested to date. Should future drilling prove the existence of Eastern Trend mineralization at South Pond, the overall strike length could exceed 1 kilometre.

Tim Froude, President and CEO of Sokoman, said: "We are extremely pleased with the early results from our 2020 field program. While we await final permits for our 10,000 m Phase 6 drilling program, we initiated a follow-up prospecting and till sampling program in an effort to define additional targets for drill testing this year. The results from South Pond support reports of boulders in the area that assayed to a maximum of 17.5 g/t Au and suggest that extensions to the high-grade Eastern Trend mineralization lie untested in the South Pond area. The boulders located by our crew are of higher average tenor than the historical values with several boulders of similar grade to the highest grades from the Eastern Trend.

A portion of the Phase 6 drilling program will address the potential of the South Pond area which will include merging the winter magnetic survey with the new float samples. We will continue to update shareholders on developments in the coming weeks in advance of starting the Phase 6 drilling in late August/ early September. We are looking forward to exciting Q3 and Q4 and expect to be generating very positive news."

COVID-19 Update

To ensure a working environment that protects the health and safety of the staff and contractors, Sokoman is operating under federally and provincially mandated and recommended guidelines during the current COVID-19 alert level.

QP

This news release has been reviewed and approved by Timothy Froude, P. Geo., a "Qualified Person" under National Instrument 43-101 and President and CEO of Sokoman Minerals Corp.

Analytical Techniques / QA/QC

All rock samples were delivered by Sokoman personnel in sealed bags directly to Eastern Analytical Ltd. in Springdale, Newfoundland for gold analysis. Eastern Analytical is an accredited assay lab that conforms to requirements of ISO/IEC 17025. All samples were submitted for assay by total pulp metallics with gravimetric finish as well as 34 element ICP analysis. Total pulp metallic analysis includes: the whole sample is crushed to -10 mesh; then pulverized to 95% -150 mesh; the total sample is weighed and screened 150 mesh; the +150 mesh fraction is fire assayed for Au, and a 30 g subsample of the -150 mesh fraction is fire assayed for Au; with a calculated weighted average of total Au in the sample reported as well. Industry accepted blanks and standards were submitted by Eastern Analytical and results reported alongside the submitted samples as per the in-house standard and duplicate policies of Eastern Analytical.

About Sokoman Minerals Corp.

Sokoman Minerals Corp. is a discovery-oriented company with projects in Newfoundland & Labrador, Canada. The Company's primary focus is its portfolio of gold projects (Moosehead, Crippleback Lake and East Alder) in Central Newfoundland on the structural corridor hosting Marathon Gold's Valentine Lake project (with measured resources of 1.16 Moz. of gold at 2.18 g/t, indicated resources of 1.53 Moz. of gold at 1.66 g/t and inferred resources of 1.53 Moz. of gold at 1.77 g/t (Marathon Gold Website) 150 km southwest of the Company's high-grade Moosehead gold project*. The Company also has a 100% interest in an early-stage antimony/gold project in Newfoundland recently optioned to White Metal Resources Inc. In Labrador, the Company has a 100% interest in the Iron Horse (Fe) project.

*Mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of mineralization hosted on the Company's property.

The Company would like to thank the Government of Newfoundland and Labrador for financial support of the project through the Junior Exploration Assistance Program. Sokoman has also applied for funding for the 2020 season.

To learn more, please contact:

Timothy Froude, P. Geo.
President & CEO
709-765-1726
tim@sokomanmineralscorp.com

Cathy Hume, Director,
Investor Relations
416-868-1079 x231
cathy@chfir.com

Website: www.sokomanmineralscorp.com

Twitter: @SokomanMinerals

Facebook: @SokomanMinerals

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward- looking statements that involve risks and uncertainties. Actual results may differ materially. Sokoman Minerals Corp. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Sokoman Minerals Corp.

SOURCE: Sokoman Minerals Corp.

ReleaseID: 599497

Sydney Inner West Electrician Committed to Providing Essential Electrical Services Amidst COVID-19 Crisis

Sydney Inner West Electrician takes extra steps to provide essential electrical services despite the impacts of COVID-19.

Inner West, Sydney, Australia – July 30, 2020 /MarketersMedia/

Sydney Inner West Electrician
45 Evans Street
Balmain New South Wales 2041
Australia
(02) 8378 2829
info@sydneyinnerwestelectrician.com.au

Sydney, Australia — Sydney Inner West Electrician recently announced that their Level 2 Electrician team remains dedicated to providing outstanding, high-quality and affordable electrical services across the local region of the Inner West of Sydney despite the effects of COVID-19. This comes at a time when residents, businesses and government are all affected by the coronavirus crisis.

Sydney Inner West Electrician based level 2 electricians believe that it is essential that the team will continue to operate and deliver home electrical inspection for faulty and loose wirings, especially most local residents are working from home. Providing uninterrupted general electrical services and assist in resolving highly technical electrical issues that local businesses may encounter. Without level 2 electricians, Inner West, Sydney residents will be left out in the dark.

“A working electricity for the home and businesses is if not the single most important contribution in maintaining a normal routine–especially in times of crisis. We have allocated more staffing resources available to ensure that our level 2 electricians are readily available, on-call to attend to all electrical services that come our way,” says Oliver Thomas, the spokesperson of Sydney Inner West Electrician.

“The safety of the local community in Inner West, Sydney is one of our priorities. Without electricity, businesses and even the local government will be placed in further danger. As they may be restricted to aid assistance in the local residents and they will be limited access on the internet for work or communication from their family and friends. Sydney Inner West Electrician is extremely proud that our electrical services continue to operate and is actively playing an important part in providing comfort in the Inner West, Sydney and help them get back on their feet during this crisis,” he added.

Sydney Inner West Electrician is a team of local electricians providing expertise in emergency electrical services and level 2 electrician services in Sydney’s Inner West residents. They regularly service suburbs in Abbotsford, Beaconsfield, Cabarita, Dobroyd Point, Earlwood and more.

Contact Info:
Name: Company Press
Email: Send Email
Organization: Sydney Inner West Electrician
Address: 45 Evans Street Balmain New South Wales 2041
Phone: (02) 8378 2829
Website: https://sydneyinnerwestelectrician.com.au/

Source URL: https://marketersmedia.com/sydney-inner-west-electrician-committed-to-providing-essential-electrical-services-amidst-covid-19-crisis/88970682

Source: MarketersMedia

Release ID: 88970682

Criminal Attorney Bryan Hershman Reveals Best Drug Charge Defense Strategy And Warns Against Talking To Police – Tacoma, WA

Leading criminal defense attorney Bryan Hershman founder at Bryan Hershman, Attorney At Law in Tacoma, WA, outlines the best drug charge defense strategy and warns against talking to police in a drug crime case. For more information please visit http://bryanhershman.com

Tacoma, WA, United States – July 30, 2020 /MM-REB/

In a recent interview, leading criminal defense attorney Bryan Hershman founder at Bryan Hershman, Attorney At Law in Tacoma, WA, revealed the best drug charge defense strategy and warns against talking to police in a drug crime case.

For more information please visit http://bryanhershman.com

When asked to comment, Hershman said, “If you’ve been arrested or been brought into the station for questioning about a drug crime case, the best thing to do is to let your legal representation communicate on your behalf with law enforcement.”

That said, there are two things that you should do when dealing with police officers.

When asked to elaborate, Hershman said, “Remember that you have the right to remain silent no matter whether you’ve been stopped on the street or have been brought into the station for questioning. The only two things you need to do is to give law enforcement your full and correct name and show them your identification.”

Hershman added, “That you should remain polite and calm and state that you do not want to speak without an attorney present.”

“Once you clearly state that you’re not willing to talk, law enforcement will not try to get any more information out of you in nine out of ten cases, he commented.

The most important reason to keep silent around police officers – even if it’s just to correct a misunderstanding – is that it could harm your defense before your case even begins.

“When in police custody, a lot of people are tempted to explain their side of the story on the false assumption that law enforcement will drop the case. Many think that the police are on their side and will exonerate them. However, this is far from the truth,” Hershman said.

He added that the main reason law enforcement conducts interviews is to gather information for probable cause to carry out an arrest or warrant to search someone’s home.

Another critical thing to keep in mind is to avoid putting anything in writing.

“Don’t sign anything given to you by the police and don’t put anything in writing when communicating with friends or family about your case including through emails and letters. Any written evidence can be collected by the police and used against you in the court of law,” he commented.

Source: http://RecommendedExperts.biz

Contact Info:
Name: Bryan Hershman
Email: Send Email
Organization: Bryan G. Hershman, Attorney At Law
Address: 1105 Tacoma Ave. S, Tacoma, WA 98402
Phone: 253-405-4360
Website: http://bryanhershman.com

Source: MM-REB

Release ID: 88970680